Explore

Rapid Read Rapid Read
University of Utah Researchers Discover Enzyme to Enhance Diabetes and Weight-Loss Drugs

University of Utah Researchers Discover Enzyme to Enhance Diabetes and Weight-Loss Drugs

Researchers at the University of Utah have identified an enzyme, PapB, that could significantly enhance the effectiveness of popular diabetes and weight-loss drugs like Ozempic and Wegovy. The enzyme works by 'tying off' peptide drugs into tight ring shapes through a process called macrocyclization, which makes them more resistant to breakdown in the body. This discovery, published in ACS Publications, suggests that these drugs could have stronger and longer-lasting effects. The research team, including co-author Karsten Eastman, highlights that this enzymatic step could improve the stability and activity duration of peptide-based drugs, potentially benefiting treatments for gastrointestinal diseases and cancer tumors as well.
Rapid Read Rapid Read
GLP-1 Drugs Linked to Weight Loss and Potential Hair Loss in U.S. Adults

GLP-1 Drugs Linked to Weight Loss and Potential Hair Loss in U.S. Adults

GLP-1 drugs, initially developed for diabetes treatment, have become widely used in the U.S. for weight loss, with an estimated 15 million American adults having used them in the past year. These medications, including semaglutide and tirzepatide, are marketed under names like Ozempic and Mounjaro. While they have contributed to a decrease in obesity rates, a new study published in Science Progress highlights a potential side effect: hair loss. The study found that hair loss was more prevalent among users taking higher doses for rapid weight loss. Dr. Paradi Mirmirani from the University of California San Francisco noted that while hair shedding can occur, it is usually temporary and manageable with proper nutrition and weight management. The study suggests that the hair loss may be linked to malnutrition due to reduced appetite, a side effect of the drugs.
Trendline Trendline
GoodRx and Novo Nordisk Collaborate to Offer Affordable Ozempic Pill

GoodRx and Novo Nordisk Collaborate to Offer Affordable Ozempic Pill

GoodRx and Novo Nordisk Collaborate to Offer Affordable Ozempic Pill
Rapid Read Rapid Read
Health Canada Approves Generic Versions of Ozempic, Impacting Drug Costs

Health Canada Approves Generic Versions of Ozempic, Impacting Drug Costs

Health Canada has approved two generic versions of the diabetes drug Ozempic, marking Canada as the first G7 country to do so. The patent for Ozempic, originally held by Novo Nordisk, expired in early January, allowing for the introduction of generic alternatives. The approved generics are from Dr. Reddy’s Laboratories and Canadian-based Apotex. These generic versions are expected to be significantly cheaper, potentially reducing costs for patients who currently pay high out-of-pocket expenses for the medication. Health Canada assures that these generics are pharmaceutically equivalent to the brand-name drug, maintaining safety and efficacy standards.
Rapid Read Rapid Read
GLP-1 Drugs Linked to Weight Loss and Potential Hair Loss in New Study

GLP-1 Drugs Linked to Weight Loss and Potential Hair Loss in New Study

A recent study has highlighted a potential side effect of GLP-1 drugs, commonly used for weight loss and diabetes management: hair loss. These medications, including popular brands like Ozempic and Wegovy, have been linked to increased instances of hair shedding, particularly among those using higher doses for rapid weight loss. The study, published in Science Progress, found that users of GLP-1 drugs were 3.4 times more likely to experience hair loss compared to non-users. Dr. Paradi Mirmirani from the University of California San Francisco noted that while hair loss can occur, it is usually temporary and manageable with proper nutrition and weight management.
Trendline Trendline
Amgen Launches Phase 3 Study for MariTide, Aiming to Revolutionize Obesity Treatment

Amgen Launches Phase 3 Study for MariTide, Aiming to Revolutionize Obesity Treatment

Amgen Launches Phase 3 Study for MariTide, Aiming to Revolutionize Obesity Treatment
Trendline Trendline
GoodRx and Novo Nordisk Introduce Self-Pay Pricing for Oral Ozempic Pill to Enhance Patient Access

GoodRx and Novo Nordisk Introduce Self-Pay Pricing for Oral Ozempic Pill to Enhance Patient Access

GoodRx and Novo Nordisk Introduce Self-Pay Pricing for Oral Ozempic Pill to Enhance Patient Access
Rapid Read Rapid Read
Health Canada Approves Generic Versions of Ozempic, Paving Way for Cost Savings

Health Canada Approves Generic Versions of Ozempic, Paving Way for Cost Savings

Health Canada has approved two generic versions of the diabetes drug Ozempic, making Canada the first G7 country to do so. The approval follows the expiration of Ozempic's patent in Canada, allowing for the introduction of generic alternatives. The approved generics, produced by Dr. Reddy’s Laboratories and Apotex, are expected to offer a more affordable option for patients. Generic medications typically cost 45 to 90 percent less than their brand-name counterparts, which could significantly reduce expenses for Canadians who rely on this medication for managing type 2 diabetes and weight loss.
Rapid Read Rapid Read
Study Finds Active Ingredient in Ozempic and Wegovy May Reduce Alcohol Use in Obese Individuals

Study Finds Active Ingredient in Ozempic and Wegovy May Reduce Alcohol Use in Obese Individuals

A recent study has shown that the active ingredient in the weight-loss drugs Ozempic and Wegovy, known as semaglutide, may help reduce alcohol use in individuals with obesity. Conducted by researchers from the Mental Health Center Copenhagen, the study involved 108 adults with both obesity and alcohol use disorder. Participants were given either a weekly semaglutide shot or a placebo for six months, alongside therapy aimed at reducing alcohol consumption. Results indicated that semaglutide reduced heavy drinking days by 41% compared to 26% in the placebo group. The study, published in The Lancet, also noted weight loss and improved blood sugar control among those taking semaglutide.
Trendline Trendline
Eli Lilly Reports Strong Q1 2026 Financial Results and Raises Full-Year Guidance

Eli Lilly Reports Strong Q1 2026 Financial Results and Raises Full-Year Guidance

Eli Lilly Reports Strong Q1 2026 Financial Results and Raises Full-Year Guidance
Trendline Trendline
FDA Halts Newron's Schizophrenia Study After Patient Death, Safety Review Underway

FDA Halts Newron's Schizophrenia Study After Patient Death, Safety Review Underway

FDA Halts Newron's Schizophrenia Study After Patient Death, Safety Review Underway
Rapid Read Rapid Read
FDA Halts Newron's Schizophrenia Study After Patient Death

FDA Halts Newron's Schizophrenia Study After Patient Death

The FDA has paused patient enrollment in Newron Pharmaceuticals' Phase 3 ENIGMA-TRS 2 trial for its schizophrenia drug, evenamide, following a patient death. The death occurred outside the U.S. and was deemed unrelated to the drug. The trial, which is testing evenamide for treatment-resistant schizophrenia, continues in other countries, including India and Argentina. Evenamide is an antipsychotic agent that works by blocking voltage-gated sodium channels to restore glutamate balance. Phase 2 data showed that evenamide reduced disease severity and psychosis symptoms, with benefits maintained over a year. Newron is also conducting another study, ENIGMA-TRS 1, across multiple regions.